Subscribe to Search results

In a letter to Dr Rotblat, Dr Christie reported the second case of seroconversion following the use of heat-treated Armour Factorate.

Published on:

Dr Harris in a letter to Dr Colvin stated that each donation was now screened for HTLV-3 but that they recognised old material may be in centres and any decision to give patients information about this potentially distressing information rested with Dr Colvin as the unit director.

Published on:

The "Morbidity and Mortality Weekly Report" stated that the Medical and Scientific Advisory Council of the National Hemophilia Foundation recently issued revised recommendations for haemophilia therapy which included that the use of non-heat-treated factor concentrates should be limited.

Published on:

The "Morbidity and Mortality Weekly Report" included figures from Cutter which showed that their heat treatment process had inactivated HTLV-3 virus to a degree that the virus was undetectable after 24 hours of heat treatment.

Published on:

The Medical and Scientific Advisory Council of the US National Hemophilia Foundation endorsed the use of heat-treated products. The CDC endorsed the use of heat treatment. It carried out the viral inactivation studies on infectious particles in cooperation with Cutter Laboratories.

Published on:

Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat-treated Factor 8 concentrate.

Published on:

An article by Robert J Gerety and Lewellys F Barker described viral inactivation as one of the measures of interest since 1975 undertaken with hopes of increasing safety of haemophiliacs from HBV.

Published on:

A paper discussed Cutter continuing to carry out studies in the hope of finding ways in which Konyne product may be rendered non-infective.

Published on:

Horowitz et al discussed their viral inactivation study in this paper which was later put into production by the New York Blood Centre.

Published on:

A memo from Linda Frith showed the total volume of returned regular material and total sales of Koate, and that for a short period of time Cutter would take a share of the NHS Factor 8 market.

Published on:

A letter from Jack Wood at Cutter stated that Cutter felt it was prudent to no longer effect sales of non-heat-treated product for use in the UK following dramatic changes in the UK regarding heat-treated Factor 8 products.

Published on:

A memo from Jack Wood stated that for inventory which could not be reallocated by Cutter US they were to seek a one year extension from NIBS to allow them to relabel and sell over the coming year into markets not yet converted to heat-treated Factor 8 products.

Published on:

In a memo on figures of Cutte's products it showed that a small short-dated batch mentioned last month had now been sold and several other contacts had shown an interest in other batches and the material had been offered for sale.

Published on:

An internal memo described the outcome of a meeting where Dr Savidge presented results of his profilate HT trials and that the results provided evidence to support Alpha's claim that Profilate HT was free from non-A non-B Hepatitis.

Published on:

Parliamentary questions discussed the issue of unscreened BPL plasma and said issuable blood products which might be contaminated with AIDS had been destroyed.

Published on:

Dr Robert Gerety and Dr David Aronson in an invited review said studies had been completed and others were underway to evaluate methods of stabilising clotting factors as heat was capable of inactivating both Hepatitis B and non-A non-B Hepatitis infectivity.

Published on:

Professor Garrott Allen wrote to Dr William Maycock stating: "As you know" Cutter's Konyne was "extraordinarily hazardous".

Published on:

Dr Maycock stated: "DHSS, in order to be able to carry with confidence its responsibility for providing the transfusion service in England and Wales, should consider fostering the development of a central transfusion research laboratory."

Published on:

Capital funding was the preserve of central government, which considered that so far as the laboratory at BPL was concerned "expenditure on up-grading should be reviewed and minimised pending a decision on the laboratory's future."

Published on:

Dr James Smith wrote: "The significance of a product demonstrably free of hepatitis risk cannot be ignored and it is essential that BPL/PFL be well placed to take advantage of such developments."

Published on: